The original investigation of 1970s into the failure of hormonal modulation of guanylate cyclase (GC) along the lines of adenylate cyclase (AC)-Cyclic AMP, indeed led to the discovery of Nitric Oxide-Cyclic GMP (NO-Cyclic GMP) signaling system in the mammalian cells. The pioneering experimental studies were launched in 1974 by the author in collaboration with Dr. Ferid Murad at the University of Virginia. Initial experiments revealed that guanylate cyclase (GC) which catalyzes the formation of guanosine 3',5'-cyclic GMP (cGMP), was stimulated by sodium azide -a nucleophilic metabolic poison, in tissue-specific manner. The tissues specificity of azide effect was found to be associated with the presence of catalase which permitted the stimulation 1 . The lack of azide response in tissues was found to be either due to lack of catalase or the presence of specific heme proteins which prevented azide-dependent activation 2 . Further investigations revealed that catalase oxidized azide to NO creating the catalase-NO complex which stimulated GC leading to enhance cGMP production. Indeed, the venting NO gas on broken-cell GC preparations led to many fold stimulation of the enzyme. Similarly, exposure of intact-cells from various tissues to azide and NO gas led to significant increases in the intracellular levels of cGMP 3 . Parallel studies, by the author, on physiological modulation of CG revealed that oxygen-radicals exerted a regulatory influence on the cGMP metabolism which was associated with various physiological events 4 . Further studies by others in the 1980s, along the lines of original investigations by this author, led to the demonstration of endogenous NO in various tissues. The formation of NO is catalyzed by nitric oxide synthase (NOS) -a heme-containing multi-enzyme system 5 which bears homology with many hemecontaining flavoproteins. NO-cGMP signaling system represents a novel bio-regulatory pathway with involvement in most organ systems' physiology. Its role is being increasingly implicated in multiple pathophysiological situations 7 . These include, hypertension, myocardial infarction, reperfusion injury, cancer, infectious disease, inflammatory disorders, etc. Measurements of NO and cGMP levels as well as evaluation of NO-cGMP system in patients offers a new opportunity and challenges to provide additional corroborative evidence in the detection and diagnosis of various metabolic diseases and disorders.
